Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. (January 2019)

• Record Type: Journal Article
• Authors: Zaleski, Katherine L.; DiNardo, James A.; Nasr, Viviane G.
• Is Part Of: Anesthesia & analgesia. Volume 128:Number 1(2019)
• Publication Date: 2019-01
• Subjects: Anesthesiology -- Periodicals; Anesthesia; Anesthesiology; Analgesia; Analgesics; Anesthesiology -- Periodicals; 617.9605
• DOI: 10.1213/ANE.0000000000002835
• Languages: English
• ISSNs: 0003-2999

Abstract

Abstract : Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin inhibitor, has found increasing utilization as a heparin alternative in the pediatric population, most commonly for the treatment of thrombosis secondary to heparin-induced thrombocytopenia. Due to the relative rarity of heparin-induced thrombocytopenia as well as the lack of Food and Drug Administration–approved indications in this age group, much of what is known regarding the pharmacokinetics and pharmacodynamics of bivalirudin in this population has been extrapolated from adult data. This narrative review will present recommendations regarding the use of bivalirudin for procedural anticoagulation in the pediatric population based on the published literature.